Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of ensuring access to treatments for debilitating diseases that are saving millions of patients from pain and possible death.
Patients rightly expect their health insurance plan to cover the best medicines based on their unique needs, at an out-of-pocket cost that makes these therapies accessible.
Insurance companies and their allies, seeking to deflect blame for increased premiums at a time of record profits, are aggressively attacking the cost of the innovative products developed by the biopharmaceutical industry, even though innovative medicines represent a small percentage of overall annual health care spending in the United States.
Caught in the crossfire are patients with chronic conditions who face increasing difficulty accessing the medications they need.
Read the full op-ed here.